Argus analyst David Toung raised the firm’s price target on Johnson & Johnson to $210 from $185 and keeps a Buy rating on the shares. The firm cites the company’s “strong” Q3 results along with its upcoming launches of new products and new indications for inline products, the analyst tells investors in a research note. The separation of the orthopedics business is also transforming J&J into a faster-growing and higher margin enterprise, Argus added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $204 from $198 at BofA
- Johnson & Johnson price target raised to $209 from $174 at Raymond James
- Johnson & Johnson price target raised to $190 from $178 at Morgan Stanley
- Balanced Outlook on Johnson & Johnson: Hold Rating Amid Strategic Shifts and Uncertainties
- Johnson & Johnson price target raised to $190 from $165 at Stifel